The broad, long term goals of this project are to discover multiple new lead compounds that are candidates for the treatment of malaria and to push these compounds as far forward as possible through preclinical studies. The health relatedness of these goals lies in the fact that there are few available drugs to treat malaria and many of those that are available are subject to clinical resistance. In fact, resistance to available drugs has been identified as the primary difficulty in the treatment of malaria. Co-therapy has emerged as the best practical solution to this problem. Therefore, the basic logical assumption of this proposal is that the development of multiple drug candidates will enable the suppression of the development of clinical resistance. This program targets two relatively unaddressed target classes: cation channels and kinases. As a back up strategy, the program also targets compounds with the same mechanism of action as existing quinolines. The research design and methods for achieving these goals involves the use of parallel medicinal chemistry;in vitro and in vivo measures of compound efficacy;and in vitro and in vivo measures of compound availability, distribution, metabolism, excretion, and toxicity. Compounds will be incrementally improved by applying cycles of these methods and refining the model that defines the overall best balance of these traits in a molecule between cycles. Compound series that fail to progress will be abandoned and progression monitored using a milestone driven model with a defined decision matrix for compound progression.
The specific aims of this program are: 1. Develop five lead series (LO) with divergent chemotypes and presumptive mechanisms of action 2. Simultaneously optimize efficacy against drug resistant P. falciparum in vitro and favorable in vitro cellular and biochemical pharmacological profiles for each series 3. Optimize up to five promising validated lead series (L1, L2) using in vivo rodent efficacy, pharmacokinetic, and toxicology models 4. Optimize up to three promising late stage lead series (L3) using in vivo simian efficacy, pharmacokinetic, and toxicology models 5. Select two preclinical candidates (PO) from these series
| Pradhan, Anupam; Siwo, Geoffrey H; Singh, Naresh et al. (2015) Chemogenomic profiling of Plasmodium falciparum as a tool to aid antimalarial drug discovery. Sci Rep 5:15930 |
| Lotharius, Julie; Gamo-Benito, Francisco Javier; Angulo-Barturen, Iñigo et al. (2014) Repositioning: the fast track to new anti-malarial medicines? Malar J 13:143 |
| Jiménez-Díaz, María Belén; Ebert, Daniel; Salinas, Yandira et al. (2014) (+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium. Proc Natl Acad Sci U S A 111:E5455-62 |
| Lowes, David; Pradhan, Anupam; Iyer, Lalitha V et al. (2012) Lead optimization of antimalarial propafenone analogues. J Med Chem 55:6087-93 |
| Zhang, Yiqun; Clark, Julie A; Connelly, Michele C et al. (2012) Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials. J Med Chem 55:4205-19 |
| Caro, Florence; Miller, Mathew G; DeRisi, Joseph L (2012) Plate-based transfection and culturing technique for genetic manipulation of Plasmodium falciparum. Malar J 11:22 |
| Guiguemde, W Armand; Shelat, Anang A; Garcia-Bustos, Jose F et al. (2012) Global phenotypic screening for antimalarials. Chem Biol 19:116-29 |
| Hwang, Jong Yeon; Kawasuji, Takashi; Lowes, David J et al. (2011) Synthesis and evaluation of 7-substituted 4-aminoquinoline analogues for antimalarial activity. J Med Chem 54:7084-93 |
| Lowes, David J; Guiguemde, W Armand; Connelly, Michele C et al. (2011) Optimization of propafenone analogues as antimalarial leads. J Med Chem 54:7477-85 |
| Ray, Sunetra; Madrid, Peter B; Catz, Paul et al. (2010) Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models. J Med Chem 53:3685-95 |
Showing the most recent 10 out of 16 publications
